A groundbreaking AI-based diagnostic tool, named Diagnosis in Susceptibility Contrast Enhancing Regions for Neuroncology (DISCERN), has been developed by the Vall d’Hebron Institute of Oncology’s (VHIO) Radiomics Group in collaboration with the…
A groundbreaking AI-based diagnostic tool, named Diagnosis in Susceptibility Contrast Enhancing Regions for Neuroncology (DISCERN), has been developed by the Vall d’Hebron Institute of Oncology’s (VHIO) Radiomics Group in collaboration with the…